Trials (Mar 2023)
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial
Abstract
Highlights 1. To find a more appropriate antithrombotic strategy for patients with CHD and GID undergoing PCI. 2. To identify whether rivaroxaban can reduce the bleeding risk of the gastrointestinal tract compared with aspirin.
Keywords